Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure-Based Design, Synthesis, and Evaluation of Novel Ponatinib Derivatives With a Significantly Altered Selectivity Profile.

ChemMedChem·2026
Same author

On the Scope of DCAF1-Recruiting PROTACs Degrading Protein Kinases.

Journal of medicinal chemistry·2026
Same author

p21-Activated Kinase (PAK) Group I-Targeting Inhibitors Promote the Dimeric Conformation in Live Cells.

ACS chemical biology·2026
Same author

The structural basis for LRRK2's activation and autoinhibition.

bioRxiv : the preprint server for biology·2026
Same author

The "one-and-a-half" minimally invasive transforaminal lumbar interbody fusion: a single-center retrospective case series.

Journal of neurosurgery. Spine·2026
Same author

Silymarin and Its Isolated Flavanonol Lignans Are Liver X Receptor Antagonists.

Archiv der Pharmazie·2026
Same journal

Development of APH003─a Highly Potent, Selective, and Orally Bioavailable IRAK4 PROTAC Degrader for the Treatment of Inflammatory Diseases.

Journal of medicinal chemistry·2026
Same journal

Recent Advances in Targeting RNA Splicing Factors with Small Molecules.

Journal of medicinal chemistry·2026
Same journal

Structure-Guided Optimization of α-Conotoxins Yields Potent and Selective Inhibitors of the Human α6β4 nAChR for Nicotine Addiction.

Journal of medicinal chemistry·2026
Same journal

Antibody-Assisted Protection from Paraoxon and Nerve Agent Model Compounds.

Journal of medicinal chemistry·2026
Same journal

Photocage Prodrug Coupled with Injectable Hydrogel for Self-Amplified Photochemotherapy.

Journal of medicinal chemistry·2026
Same journal

GPX4-Targeting Phenolato Zr<sup>IV</sup> Complexes Induce Ferroptosis and Lysosome-Dependent Cell Death for Immunotherapy of Chemoresistant Cancer.

Journal of medicinal chemistry·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

First Structure-Activity-Relationship Study of Potent G2A Antagonists.

Victor Hernandez-Olmos1,2, Jan Heering1,2, Felix F Lillich3

  • 1Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany.

Journal of Medicinal Chemistry
|June 11, 2026
PubMed
Summary
This summary is machine-generated.

Researchers discovered new G2A antagonists, crucial for treating neuropathic pain and breast cancer. This study details their development and structure-activity relationships, identifying key features for potent G2A inhibition.

More Related Videos

Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

Strategic Screening and Characterization of the Visual GPCR-mini-G Protein Signaling Complex for Successful Crystallization
09:19

Strategic Screening and Characterization of the Visual GPCR-mini-G Protein Signaling Complex for Successful Crystallization

Published on: March 16, 2020

Related Experiment Videos

Last Updated: Jun 13, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

Strategic Screening and Characterization of the Visual GPCR-mini-G Protein Signaling Complex for Successful Crystallization
09:19

Strategic Screening and Characterization of the Visual GPCR-mini-G Protein Signaling Complex for Successful Crystallization

Published on: March 16, 2020

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Oncology

Background:

  • G2A inhibition is a promising therapeutic strategy for oxaliplatin-induced neuropathic pain (OINP) and breast cancer.
  • A limited number of G2A antagonists are currently available, highlighting a need for novel compounds.

Purpose of the Study:

  • To discover and characterize a novel series of G2A antagonists.
  • To conduct the first comprehensive structure-activity relationship (SAR) study for G2A antagonists.
  • To identify key molecular features responsible for potent G2A inhibition.

Main Methods:

  • Rational drug design approach was employed for systematic structural modifications.
  • Structure-activity relationship (SAR) analysis was performed to correlate structural changes with G2A receptor binding and functional activity.
  • Compound screening included assessment of G2A receptor binding, functional activity, and selectivity across G protein-coupled receptors (GPCRs).

Main Results:

  • A novel series of G2A antagonists was successfully developed.
  • The SAR study elucidated critical molecular determinants for potent G2A inhibition.
  • Two newly synthesized compounds demonstrated submicromolar activity against G2A.
  • These compounds exhibited an acceptable selectivity profile among GPCRs.

Conclusions:

  • The discovery of novel G2A antagonists offers potential new therapeutic options for OINP and breast cancer.
  • The comprehensive SAR data provides a foundation for further optimization of G2A antagonists.
  • The identified compounds represent promising leads for drug development targeting G2A.